Global Pneumonia Vaccine Market Outlook 2020

Description: Introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, decreases the rates of clinical pneumonia even in unvaccinated children, a classic example of herd immunity. With a greater number of serotypes in current vaccines, there has been more disease reduction in both vaccinated and unvaccinated populations. As vaccines evolve, similar improvements can be expected.

The Pneumonia vaccine market for 2014, which has been estimated at US$ 5.9 Billion, is expected to reach US$ 11 Billion by 2020, growing at a CAGR of 11.1% over the six year period. It has been noted that although USA and Europe are the major shareholders in the market, the developing regions are expected to account for a significant share too. This shift can be attributed to the rising incidences as well as the increasing purchasing power of the populations in these regions. Government's focus on a preventive healthcare strategy to cut down costs is also set to play a major role in the growth of the vaccine industry.

As vaccines are highly regulated to ensure patients and users have access to safe and effective medicines, the regulatory scenarios for vaccine approval and licensing has also been discussed. It has been noted that individual governments determine which products can be marketed in their countries and many have state-regulated systems governing product pricing. The three major players in the industry are GlaxoSmithKline, Pfizer and Merck.

Contents:
1. Analyst View
2. Research Methodology
3. Pneumococcal Disease and Vaccine
4. Global Pneumonia Vaccine Market Outlook 2020
   4.1 Key Geographical Markets
5. Regulatory Overview
   5.1 United States
   5.2 Europe
   5.3 Rest of the World
   5.3.1 India
   5.3.2 China
   5.3.3 Japan
6. Competitive Assessment
   6.1 Market Share of Major Players
   6.2 Company Profiles
      6.2.1 GlaxoSmithKline
         6.2.1.1 Business Overview
         6.2.1.2 Key Financials
         6.2.1.3 Strengths and Weaknesses
      6.2.2 Pfizer
         6.2.2.1 Business Overview
         6.2.2.2 Key Financials
         6.2.2.3 Strengths and Weaknesses
      6.2.3 Merck
         6.2.3.1 Business Overview
         6.2.3.2 Key Financials
         6.2.3.3 Strengths and Weaknesses

List of Tables and Figures:
Table 4-1: Current levels of coverage for interventions that prevent (vaccination) Pneumonia
Table 6-1: GSK - Pneumonia Vaccine Portfolio
Table 6-2: GSK - Key Financials (Million GBP), 2012-2014
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Pfizer - Pneumonia Vaccine Portfolio
Table 6-5: Pfizer - Key Financials (Million US$), 2012-2014
Table 6-6: Pfizer - Strengths and Weaknesses
Table 6-7: Merck - Pneumonia Vaccine Portfolio
Table 6-8: Merck - Key Financials (Millions US$), 2012-2014
Table 6-9: Merck - Strengths and Weaknesses

Figure 4-1: Relation between Country Income and Under-5 Child Deaths from Pneumonia
Figure 4-2: Impact of Childhood Conjugate Pneumococcal Immunization on Incidence of Disease in < 5 Years of Age
Figure 4-3: Herd Immunity Impact of Childhood Pneumococcal Immunization in the US
Figure 4-4: Pneumonia Vaccine Market (Million US$), 2009-2014
Figure 4-5: Pneumonia Vaccine Market (Million Doses), 2009-2014
Figure 4-6: Pneumonia Vaccine Market (Million US$), 2014-2020
Figure 4-7: Pneumococcal Vaccine Market by Geography (%), 2014
Figure 4-8: Percentage of Adults Aged 65 and over who had ever received a Pneumococcal Vaccination: United States, 1997-2013
Figure 4-9: Age-Adjusted Death Rates for Pneumonia in 2013: United States, 1999-2013
Figure 6-1: Pneumococcal Vaccine Market Value Share by Players (%), 2014
Figure 6-2: Pneumococcal Vaccine Market Volume Share by Players (%), 2014
Figure 6-3: GSK - Revenue by Geographic Segment (%), 2014
Figure 6-4: GSK - Revenue by Business Segment (%), 2014
Figure 6-5: GSK - Break-up of Revenue of Pharmaceutical and Vaccines Business Segment (%), 2014
Figure 6-6: GSK - Synflorix Sales (Million GBP), 2010-2014
Figure 6-7: Pfizer - Revenue by Geography (%), 2014
Figure 6-8: Pfizer - Revenue by Business Segment (%), 2014
Figure 6-9: Pfizer - Prevnar Family Sales (Million USD), 2010-2014
Figure 6-10: Merck - Revenue by Business Segment (%), 2014
Figure 6-11: Merck - Revenue by Geography (%), 2014
Figure 6-12: Merck - Pneumovax 23 Sales (Million USD), 2010-2014

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit 
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Pneumonia Vaccine Market Outlook 2020  
Web Address:  http://www.researchandmarkets.com/reports/3275280/  
Office Code: SC6IJD7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Options</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>Single User:</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td></td>
<td>USD 1700 + USD 57 S/H</td>
</tr>
<tr>
<td>CD-ROM:</td>
<td></td>
<td>USD 1700 + USD 57 S/H</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>Enterprisewide:</td>
<td>USD 2500</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>Sort code</th>
<th>Swift code</th>
<th>IBAN number</th>
<th>Bank Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>833 130 83</td>
<td>98-53-30</td>
<td>ULSBIE2D</td>
<td>IE78ULSB9853083313083</td>
<td>Ulster Bank,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>27-35 Main Street,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blackrock, Co. Dublin,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World